<p><em>顶级医疗机构的回顾性分析突显了人工智能解决方案在发现之前未被发现的癌症和正确定位乳腺 X 光片上可疑区域的能力</em></p>
<p>马尔伯勒，马萨诸塞州 --（商业资讯）-- 霍洛捷公司（Nasdaq: HOLX），一家致力于改善女性健康的领先医疗技术公司，今天宣布了新的数据，突显了该公司的先进人工智能驱动的乳腺 X 光解决方案如何帮助检测更多乳腺癌。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg"/></p>
<p>霍洛捷的人工智能驱动乳腺 X 光技术</p>
<p>“在霍洛捷，我们不断推动自己进行创新，提升技术的质量和可靠性，” 乳腺与骨骼健康解决方案总裁马克·霍瓦斯（Mark Horvath）表示。“这项研究强调了人工智能揭示可能被隐藏的癌症的潜力，同时也为我们提供了指导未来创新发展的关键见解。随着我们根据客户和提供者的反馈不断推进这项技术，我们期待看到它在现实世界中的影响。”</p>
<p>在《美国放射学杂志》上发表的一项新研究中，波士顿麻省总医院的研究人员对 7500 例使用霍洛捷的 Genius AI®检测解决方案进行的数字乳腺断层摄影（3D 乳腺 X 光）筛查进行了回顾性分析。在 2016 年至 2019 年间进行的 7500 例检查中，有 100 例假阴性病例，即被解读为阴性的乳腺 X 光片，但在接下来的年份中被诊断为乳腺癌。Genius AI 检测解决方案将大约三分之一（32%）的这些病例标记为可疑区域，准确识别出随后被诊断为乳腺癌的位置。</p>
<p>在放射科医生之前识别的 500 例乳腺癌病例中，Genius AI 检测技术标记了近 90% 的病例，并正确定位了它们的位置。该人工智能技术在研究中更可能标记侵袭性导管癌和淋巴结阳性癌症，而不太可能标记侵袭性小叶癌和 I 级侵袭性癌症。</p>
<p>研究中提到的一个假阴性病例涉及一名 54 岁的女性，她的结果最初被解读为阴性。十一个月后，她因注意到左乳腺有肿块而返回就医，并被诊断为 I 级侵袭性导管癌。在对初次筛查乳腺 X 光片的回顾性评估中，人工智能算法标记并正确定位了癌症所在的可疑区域。</p>
<p>“在这项研究中，人工智能不仅将该病例识别为可疑并需要进一步审查，而且还正确定位了关注区域，” 麻省总医院布里格姆妇女医院乳腺影像质量副主任、哈佛医学院放射学副教授马尼莎·巴尔（Dr. Manisha Bahl）表示。“虽然还需要进一步研究，但这些发现是有希望的，突显了人工智能在未来重新定义乳腺癌检测的巨大潜力。”</p>
<p><strong>研究局限性</strong></p>
<p>本研究是在一个以白人患者为主的单一学术医疗中心进行的，使用的是霍洛捷的 Genius AI 检测 2.0 软件，结果可能无法推广到其他实践环境或其他基于人工智能的算法。此外，某些子组内的小样本量限制了统计能力和子组分析的普遍性。该研究还未评估人工智能对患者结果的影响或其在现实临床工作流程中的整合。</p>
<p><strong>关于 Genius AI 检测解决方案</strong></p>
<p>霍洛捷的 Genius AI 检测解决方案是一种创新的乳腺 X 光筛查技术，旨在定位可能代表乳腺癌的病变。可疑区域在放射科医生的工作站上被突出显示，以支持智能、果断的解读。霍洛捷的深度学习算法通过大量多样化的患者基础积累数据，提供丰富的见解和智能。有关更多信息，请访问 <strong>Genius AI 检测技术</strong>。</p>
<p><strong>关于霍洛捷公司</strong></p>
<p>霍洛捷公司是全球女性健康领域的领导者，致力于开发创新医疗技术，有效检测、诊断和治疗健康状况，并提高全球护理标准。要了解更多信息，请访问 www.hologic.com，并在 LinkedIn、Facebook、X、Instagram 和 YouTube 上与我们联系。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿可能包含涉及风险和不确定性的前瞻性信息，包括关于霍洛捷产品使用的声明。不能保证这些产品将实现此处描述的好处，或在个别患者身上以任何特定方式复制这些好处，因为使用产品的实际效果只能逐案确定。此外，不能保证这些产品将商业成功或达到任何预期的销售水平。霍洛捷明确声明不承担任何义务或承诺，公开发布任何此类声明的更新或修订，以反映任何期望的变化或任何此类数据或声明所基于的事件、条件或情况的变化。</p>
<p>霍洛捷、确定科学和 Genius AI 是霍洛捷公司及其子公司在美国和/或其他国家的商标和/或注册商标。</p>
<p><strong>参考文献</strong></p>
<p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. 商业人工智能（AI）工具用于筛查数字乳腺断层摄影：与基于 AI 的乳腺癌检测相关的因素。AJR Am J Roentgenol.2025 年 12 月 3 日。doi: 10.2214/AJR.25.33792。提前在线出版。PMID: 41334895。</p>
<p>来源：霍洛捷公司</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ"/></p>
<p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20251216784478/en/</p>
<p><strong>媒体联系人</strong></p>
<p>Bridget Perry</p>
<p>高级总监，企业传播部</p>
<p>(+1) 508.263.8654</p>
<p>bridget.perry@hologic.com</p>
<p><strong>投资者联系人</strong></p>
<p>Michael Watts</p>
<p>企业副总裁，投资者关系</p>
<p>(+1) 858.410.8514</p>
<p>michael.watts@hologic.com</p>
<p>来源：Hologic, Inc.</p>

豪洛捷

<p>霍洛捷的人工智能乳腺摄影技术在一项对 7500 例检查的研究中标记了 32% 的最初漏诊乳腺癌病例。该技术准确识别了可疑区域，突显了其改善癌症检测的潜力。这项在马萨诸塞州总医院进行的研究显示了人工智能重新定义乳腺癌检测的能力，尽管由于样本量和人口特征的限制，仍存在一些局限性。霍洛捷继续在女性健康技术领域进行创新</p>

<p><em>Retrospective analysis at top-tier medical facility highlights AI solution’s ability to help spot previously missed cancers and correctly localize suspicious areas on mammograms</em></p>
<div class="lb-trans"><p><em>顶级医疗机构的回顾性分析突显了人工智能解决方案在发现之前未被发现的癌症和正确定位乳腺 X 光片上可疑区域的能力</em></p>
</div><p>MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a leading medical technology company dedicated to improving women’s health, today announced new data that highlights how the company’s advanced AI-powered mammography solution can aid in detecting more breast cancers.</p>
<div class="lb-trans"><p>马尔伯勒，马萨诸塞州 --（商业资讯）-- 霍洛捷公司（Nasdaq: HOLX），一家致力于改善女性健康的领先医疗技术公司，今天宣布了新的数据，突显了该公司的先进人工智能驱动的乳腺 X 光解决方案如何帮助检测更多乳腺癌。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg" alt="" original-src="https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg"/></p>
<p>Hologic’s AI-Powered Mammography Technology</p>
<div class="lb-trans"><p>霍洛捷的人工智能驱动乳腺 X 光技术</p>
</div><p>“At Hologic, we are constantly pushing ourselves to innovate and enhance the quality and reliability of our technologies,” said Mark Horvath, President of Breast and Skeletal Health Solutions. “This study underscores AI’s potential to uncover cancers that might otherwise remain hidden, while also giving us critical insights to guide the development of future innovations. As we continue to advance this technology based on customer and provider feedback, we’re excited to see its impact in real-world settings.”</p>
<div class="lb-trans"><p>“在霍洛捷，我们不断推动自己进行创新，提升技术的质量和可靠性，” 乳腺与骨骼健康解决方案总裁马克·霍瓦斯（Mark Horvath）表示。“这项研究强调了人工智能揭示可能被隐藏的癌症的潜力，同时也为我们提供了指导未来创新发展的关键见解。随着我们根据客户和提供者的反馈不断推进这项技术，我们期待看到它在现实世界中的影响。”</p>
</div><p>In a new study1 published in the <em>American Journal of Roentgenology</em>, researchers at Massachusetts General Hospital in Boston performed a retrospective analysis of 7,500 digital breast tomosynthesis (3D mammography) screening exams using Hologic’s Genius AI® Detection solution. Among the 7,500 exams performed between 2016 and 2019, there were 100 false-negative cases, which are mammograms read as negative but followed by a breast cancer diagnosis within the next year. The Genius AI Detection solution marked approximately one-third (32%) of these cases as including areas of suspicion, accurately identifying the location where breast cancer was subsequently diagnosed.</p>
<div class="lb-trans"><p>在《美国放射学杂志》上发表的一项新研究中，波士顿麻省总医院的研究人员对 7500 例使用霍洛捷的 Genius AI®检测解决方案进行的数字乳腺断层摄影（3D 乳腺 X 光）筛查进行了回顾性分析。在 2016 年至 2019 年间进行的 7500 例检查中，有 100 例假阴性病例，即被解读为阴性的乳腺 X 光片，但在接下来的年份中被诊断为乳腺癌。Genius AI 检测解决方案将大约三分之一（32%）的这些病例标记为可疑区域，准确识别出随后被诊断为乳腺癌的位置。</p>
</div><p>Of the 500 breast cancer cases previously identified by radiologists, the Genius AI Detection technology flagged almost 90% and correctly localized their locations. The AI technology was more likely to flag invasive ductal carcinomas and lymph node-positive cancers in the study. It was less likely to flag invasive lobular carcinomas and grade I invasive carcinomas.</p>
<div class="lb-trans"><p>在放射科医生之前识别的 500 例乳腺癌病例中，Genius AI 检测技术标记了近 90% 的病例，并正确定位了它们的位置。该人工智能技术在研究中更可能标记侵袭性导管癌和淋巴结阳性癌症，而不太可能标记侵袭性小叶癌和 I 级侵袭性癌症。</p>
</div><p>One instance of a false-negative case flagged by AI cited in the study involved a 54-year-old woman whose results were initially interpreted as negative. Eleven months later, she returned to her doctor after noticing a lump in her left breast and was diagnosed with grade 1 invasive ductal carcinoma. On retrospective evaluation of the initial screening mammogram, the AI algorithm marked and correctly localized the area where the cancer was located as suspicious.</p>
<div class="lb-trans"><p>研究中提到的一个假阴性病例涉及一名 54 岁的女性，她的结果最初被解读为阴性。十一个月后，她因注意到左乳腺有肿块而返回就医，并被诊断为 I 级侵袭性导管癌。在对初次筛查乳腺 X 光片的回顾性评估中，人工智能算法标记并正确定位了癌症所在的可疑区域。</p>
</div><p>“In this study, not only did the AI identify the case as suspicious and warranting additional review, but it also correctly localized the region of interest,” said Dr. Manisha Bahl, MD, MPH, Associate Director of Quality for Breast Imaging at Mass General Brigham and Associate Professor of Radiology at Harvard Medical School. “While additional research is needed, these findings are promising and highlight AI’s tremendous potential to redefine breast cancer detection in the years ahead.”</p>
<div class="lb-trans"><p>“在这项研究中，人工智能不仅将该病例识别为可疑并需要进一步审查，而且还正确定位了关注区域，” 麻省总医院布里格姆妇女医院乳腺影像质量副主任、哈佛医学院放射学副教授马尼莎·巴尔（Dr. Manisha Bahl）表示。“虽然还需要进一步研究，但这些发现是有希望的，突显了人工智能在未来重新定义乳腺癌检测的巨大潜力。”</p>
</div><p><strong>Study Limitations</strong></p>
<div class="lb-trans"><p><strong>研究局限性</strong></p>
</div><p>This study was performed at a single academic medical center with a predominantly Caucasian patient population and was conducted with Hologic’s Genius AI Detection 2.0 software, and the results may not be generalizable to other practice settings or to other AI-based algorithms. Additionally, the small sample sizes within certain subgroup limit the statistical power and generalizability of the subgroup analyses. The study also did not evaluate the impact of AI on patient outcomes or its integration into real-world clinical workflows.</p>
<div class="lb-trans"><p>本研究是在一个以白人患者为主的单一学术医疗中心进行的，使用的是霍洛捷的 Genius AI 检测 2.0 软件，结果可能无法推广到其他实践环境或其他基于人工智能的算法。此外，某些子组内的小样本量限制了统计能力和子组分析的普遍性。该研究还未评估人工智能对患者结果的影响或其在现实临床工作流程中的整合。</p>
</div><p><strong>About Genius AI Detection Solution</strong></p>
<div class="lb-trans"><p><strong>关于 Genius AI 检测解决方案</strong></p>
</div><p>Hologic’s Genius AI Detection solution is an innovative mammography screening technology designed to locate lesions likely to represent breast cancer. Suspicious areas are highlighted at radiologists’ workstations for concurrent reading to support smart, decisive interpretation. Hologic's deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence. For more information, please visit <strong>Genius AI Detection Technology</strong>.</p>
<div class="lb-trans"><p>霍洛捷的 Genius AI 检测解决方案是一种创新的乳腺 X 光筛查技术，旨在定位可能代表乳腺癌的病变。可疑区域在放射科医生的工作站上被突出显示，以支持智能、果断的解读。霍洛捷的深度学习算法通过大量多样化的患者基础积累数据，提供丰富的见解和智能。有关更多信息，请访问 <strong>Genius AI 检测技术</strong>。</p>
</div><p><strong>About Hologic, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于霍洛捷公司</strong></p>
</div><p>Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.</p>
<div class="lb-trans"><p>霍洛捷公司是全球女性健康领域的领导者，致力于开发创新医疗技术，有效检测、诊断和治疗健康状况，并提高全球护理标准。要了解更多信息，请访问 www.hologic.com，并在 LinkedIn、Facebook、X、Instagram 和 YouTube 上与我们联系。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.</p>
<div class="lb-trans"><p>本新闻稿可能包含涉及风险和不确定性的前瞻性信息，包括关于霍洛捷产品使用的声明。不能保证这些产品将实现此处描述的好处，或在个别患者身上以任何特定方式复制这些好处，因为使用产品的实际效果只能逐案确定。此外，不能保证这些产品将商业成功或达到任何预期的销售水平。霍洛捷明确声明不承担任何义务或承诺，公开发布任何此类声明的更新或修订，以反映任何期望的变化或任何此类数据或声明所基于的事件、条件或情况的变化。</p>
</div><p>Hologic, The Science of Sure and Genius AI are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.</p>
<div class="lb-trans"><p>霍洛捷、确定科学和 Genius AI 是霍洛捷公司及其子公司在美国和/或其他国家的商标和/或注册商标。</p>
</div><p><strong>References</strong></p>
<div class="lb-trans"><p><strong>参考文献</strong></p>
</div><p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. Commercial Artificial Intelligence (AI) Tool for Screening Digital Breast Tomosynthesis: Factors Associated With AI-Based Breast Cancer Detection. AJR Am J Roentgenol. 2025 Dec 3. doi: 10.2214/AJR.25.33792. Epub ahead of print. PMID: 41334895.</p>
<div class="lb-trans"><p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. 商业人工智能（AI）工具用于筛查数字乳腺断层摄影：与基于 AI 的乳腺癌检测相关的因素。AJR Am J Roentgenol.2025 年 12 月 3 日。doi: 10.2214/AJR.25.33792。提前在线出版。PMID: 41334895。</p>
</div><p>SOURCE: Hologic, Inc.</p>
<div class="lb-trans"><p>来源：霍洛捷公司</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251216784478r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251216784478/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20251216784478/en/</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系人</strong></p>
</div><p>Bridget Perry</p>
<div class="lb-trans"><p>Bridget Perry</p>
</div><p>Senior Director, Corporate Communications</p>
<div class="lb-trans"><p>高级总监，企业传播部</p>
</div><p>(+1) 508.263.8654</p>
<div class="lb-trans"><p>(+1) 508.263.8654</p>
</div><p>bridget.perry@hologic.com</p>
<div class="lb-trans"><p>bridget.perry@hologic.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系人</strong></p>
</div><p>Michael Watts</p>
<div class="lb-trans"><p>Michael Watts</p>
</div><p>Corporate Vice President, Investor Relations</p>
<div class="lb-trans"><p>企业副总裁，投资者关系</p>
</div><p>(+1) 858.410.8514</p>
<div class="lb-trans"><p>(+1) 858.410.8514</p>
</div><p>michael.watts@hologic.com</p>
<div class="lb-trans"><p>michael.watts@hologic.com</p>
</div><p>Source: Hologic, Inc.</p>
<div class="lb-trans"><p>来源：Hologic, Inc.</p>
</div>

Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams | HOLX Stock News

豪洛捷的 AI 驱动乳腺 X 光检查技术在一项包含 7500 次筛查的研究中，标记了三分之一最初被解释为阴性的乳腺癌病例 | HOLX 股票新闻